Nonsteroid anti-inflammatory drugs are often used to treat myalgias and arthralgias in enteroviral infections, but their effects on acute viral myocarditis are unknown. The effect of the nonsteroidal anti-inflammatory drug, ibuprofen, on acute viral myocarditis was studied in 75 four week old male BALB/c mice infected with 1.75 x 10 7 plaque-forming units of Coxsackie virus B3 on day O. Ibuprofen was given intraperitoneally at a dose of 15 mg/kg body weight daily. The mice were assigned to four groups-Group I, 18 uninfected mice given ibuprofen on days 1 to 14; Group II, 18 infected, untreated mice; Group III, 20 infected mice given ibuprofen on days 1 to 14; and Group IV, 17 infected mice given ibuprofen on days 7 to 14. Nine animals in Group I, eight in Group II and seven in Group III were killed on day 1; the remaining mice were killed on day 14. Heart viral cul• tures and histologic analysis were done. Cultures at days 7 and 14 were all negative. Inflammation and necrosis analyzed in each animal were graded 0 to 4, with grade 4 representing widespread inflammation and necrosis.
The emerging hypothesis that viral myocarditis may lead to chronic idiopathic dilated cardiomyopathy underscores the importance of a more complete understanding of the role of the initial viral infection. The viral infection incites the complex immunologic responses that lead to persistent myo• cardial inflammation, fibrosis and, ultimately, cardio• myopathy. Moreover, because specific treatment for most primary myocardial diseases does not exist, a further un• derstanding of the pathogenesis of viral-initiated myocardial inflammation may lead to the development of therapy strat-
The heart was histologically normal in all 18 unin• fected mice (Group I) given ibuprofen only. Inflamma• tion and necrosis were not significantly different in Group II (infected, untreated) and Group III (infected, treated beginning day 1) mice killed at day 7. Inflammation scores of mice killed on day 14 were 2.1 ± 0.6 (Group II), 3.1 ± 0.7 (Group III) and 1.9 ± 1.0 (Group IV infected, treated days 7 to 14). Necrosis scores of mice killed on day 14 were 1.5 ± 0.8 (Group II), 3.0 ± 0.9 (Group III) and 2.7 ± 1.1 (Group IV). When compared with Group II (infected, but flot treated), both inflam• mation and necrosis were significantly worse in Group III (p < 0.01) and Group IV (p < 0.05). These results indicate that ibuprofen worsens ntyocardial inflamma• tion and necrosis during acute viral myocarditis. This effect, not attributable to viral pet'ltlstence in the myo• cardium, may be related to immunomodulating prop• erties of ibuprofen on prostaglandin-sensitive mononu• clear cells. (J Am Coll CardioI1985; 6:1078-82) egies designed to treat the cause rather than ameliorate the congestive heart failure of dilated cardiomyopathy.
The murine Coxsackie 83 myocarditis model is ideally suited for studies attempting to modify immune responses in acute and chronic myocarditis. Multiple lines of inves• tigation have documented the evolution of this myocarditis from an acute viral syndrome to a chronic state of fibrosis• a scenario that seems to parallel the pathophysiology of the human disease (1). After Coxsackie 83 infection, acute myocarditis ensues, but appropriate 8 cell and monocyte responses effect clearance of the virus. The myocardial his• tologic changes that occur early are patchy and usually con• sist of sporadk myonecrosis. However, a mononuclear in• flammatory infiltrate persists in the heart of appropriate mouse strains for up to 6 months after the initial infection. His• tologic analysis of these animals reveals fibrosis, dystrophic mineralization and myocardial hypertrophy. These progress to mural thrombi, myocardial disintegration and fibrotic scarring by 15 months (2).
The murine disease then appears to be two-phased. The initial phase is characterized by myocyte viral infection with reactive B cell, humoral antibody and monocyte responses, an appropriate rate of viral clearance by 10 days and a low fatality rate. The second, nonviral phase is characterized by absence of detectable virus in the face of mononuclear in• filtrates that consist of monocytes, T lymphocytes and prob• ably natural killer (NK) cells that perpetuate the disease to a terminal state of dilated cardiomyopathy (2, 3) . The dis• sociation of the acute from the chronic phase bears a strong similarity to the human disease and has prompted the use of this model for the evaluation of immunopharmacologic interventions that may be efficacious in myocarditis• cardiomyopathy.
The effects of nonsteroid anti-inflammatory drugs on in• flammatory responses are presumably based on the common denominator of their ability to perturb prostaglandin and lipooxygenase synthetic pathways (4) . These drugs are usu• ally considered to be a primary focus of therapeutic interest in diseases with either an infectious or a noninfectious in• flammatory basis. Thus, we believed that an initial step in seeking means to modify viral heart inflammation would be to evaluate the role of nonsteroid anti-inflammatory drugs in altering myocardial necrosis and the unfavorable outcome of myocardial destruction in the murine model.
Methods
Animals. Seventy-five 3 week old male BALB/c mice were held for 7 days before the experiment in a single, self• contained animal isolation unit to exclude animals with prior disease (Harlan Laboratory). The mice were maintained in disposable, filter-topped cages and handled with gloves by gowned and masked personnel. The intraperitoneal route was used for viral infection and all drug administration. All intraperitoneal injections were given in a 0.5 ml volume by tuberculin syringe with a 27 gauge needle after iodine-al• cohol abdominal skin preparation. intraperitoneally daily at a dose of 15 mg/kg, the actual dose for each experiment being calculated from mouse weight at the time of infection. This drug amount is comparable with an average daily dose used in humans for synovial inflam• mation. The date of viral infection was termed day 0; the day of study completion was day 14. On day 0, 55 mice were infected; 73 mice were assigned to one of four groups. Group I consisted of 18 noninfected mice treated with ibu• profen on days 10 to 14, Group II consisted of 18 infected mice that were treated with diluent only for the duration of the experiment, Group III consisted of 20 infected mice given ibuprofen daily from days I through 14 and Group IV consisted of 17 mice infected at day 0 but receiving ibuprofen daily on days 7 through 14. On day 7, 24 mice were killed. The remaining survivors were killed on day 14.
Histopathologic analysis. After cervical dislocation, the hearts were immediately removed for histopathologic anal• ysis. Each heart was divided into two coronal sections. The basal section was snap-frozen and held at -70°C for viral assay. After thawing, the sections were minced with a sterile scalpel, suspended in I ml Roswell Park Memorial Institute 1640 and homogenized in a glass tissue grinder. The sus• pension was centrifuged at 8,000 rpm for 10 minutes at 4°C; supernatants harvested and frozen at -70°C until assay. Serial lO-fold dilutions of heart homogenates in minimal essential medium were layered on confluent 72 hour old VERO cells that had been grown in 96 well microtiter plates (Falcon). Cytopathic effects were checked daily for 7 days and virus was determined by presence or absence of cell destruction. The remainder of the heart was immersed in buffered formalin and Bouin' s solution and processed by semi automated dehydration and stained with hematoxylin• eosin and Masson's trichrome stains.
Data analysis. The slides were coded and read inde• pendently by two of the investigators blinded to experi• mental group designations. Necrosis and inflammation were the two morphologic abnormalities analyzed, and each was graded according to the semiquantitative scoring system established by Woodruff and Woodruff (5) 
Results
Histologic scores in mice killed on day 7. One mouse died before the experiment and another on day I from a complication of the drug injection. There were no other complications secondary to drug injection during the study. Group I (n = 9) 0 0
Group II (n = 8)
1.6 ± 0.6; 1.2 ± 0.9; (1-2.5) (0-2.5)
Group III (n = 7)
1.8 ± 1.0; 1.4 ± 1.2; (1-3.5) (0-3)
Results are expressed as mean :t SD; range of values shown in pa• rentheses. Group I = noninfected mice given ibuprofen on days I to 14; Group II = infected mice given diluent only; Group III = infected mice given ibuprofen beginning on day I.
One mouse in Group III was dead on day 14; three mice in Group IV died between days 12 and 14. These hearts could not be examined because of cannibalization. Nine animals in Group I, 8 in Group II and 7 in Group III were killed on day 7. Their histologic scores are shown in Table I . None of the drug-treated, but uninfected, mice had evidence of any inflammation or necrosis. The histologic changes in infected mice were not significantly different from those in infected, drug-treated mice.
Histologic scores in mice killed on day 14. Nine ani• mals in Group I, 10 in Group II, 12 in Group III and 14 in Group IV were killed on day 14. Inflammation and necrosis scores of the groups are depicted in Table 2 .
A spectrum of inflammatory infiltrates and myofibrillar necrosis (Fig. 1) was present in the three experimental groups. Only 2 of 10 mice in Group II (virus only) had severe inflammation (score::::: 3), whereas 9 mice (75%) in Group III (virus plus ibuprofen from day I) and 10 (71 %) in Group IV (virus plus ibuprofen from day 7) had severe inflammation (score::::: 3) (p < 0.05). Only one mouse in Group II had severe myofibrillar necrosis, whereas eight (66%) in Group III and nine (64%) in Group IV had severe necrosis (score::::: 3) (p < 0.05). Three animals (25%) in Group III and four (28%) in Group IV had severe, wide• spread inflammation (score ::::: 4); four animals (33%) in Group III and four (28%) in Group IV had severe, wide- Group IV (n = 14)
2.9 ± I.ot; 2.7 ± l.l t; (1-4)
(1-4) *p < 0.01 compared with Group II; tp < 0.05 compared with Group II. Results are expressed as mean :t SD; range of values shown in paren• theses. Groups I to III as in Table I . Group IV = infected mice given ibuprofen on days 7 to 14. spread necrosis (score ::::: 4). No animal in Group I (drug only) had any inflammation or necrosis. Necrosis in the infected and drug-treated animals killed on day 14 was markedly different and characterized by extreme amounts of dystrophic calcification and gaping areas of necrosis sur• rounded by dense bands of mononuclear infiltrates (Fig. 2) . This could be contrasted with the thin bands of mononuclear infiltrates and much less calcification and focal density of necrosis in infected mice that were not drug-treated (Fig.  3) . Viral cultures of myocardium done at day 7 and day 14 were negative in all experimental animals.
Discussion
The experiment presented here demonstrates conclu• sively that ibuprofen, when given in the acute phase of murine myocarditis, exacerbates myocardial inflammation and necrosis. The effects of ibuprofen on chronic myocar• ditis have not been investigated, Although nonsteroid anti• inflammatory drugs are commonly used to treat the myalgias and arthralgias of viral infection, we chose to study ibu• profen for more basic than clinical reasons. The marked disparity between the drug-treated, virus-infected group and the virus-infected only group of animals should stimulate concern at the clinical level because many patients with viral infection are either purposely or coincidentally treated with nonsteroid anti-inflammatory drugs.
Therapeutic interventions that alter Coxsackie virus B3 myocarditis. Other drugs have already been identified that alter Coxsackie virus B3 heart disease. Administering corticosteroids before Coxsackie virus B3 infection or as late as the sixth day after infection results in extensive my• ocyte necrosis, viral persistence in the host and unusually high mortality (6) . Presumably these agents inhibit the mi• gration of inflammatory cells into the heart and also their ability to eliminate the virus. A more basic mechanism of their deleterious influence on early viral infection may be their recently described ability to inhibit interleukin-2 syn• thesis (7) . Levamisole also has amplified cytotoxic activity of lymphocytes during Coxsackie virus B3 infection and has been associated with a significant increase in myocarditis when used in the murine Coxsackie virus B3 model (8) . In contrast, therapeutic interventions that diminish T lympho• cyte function have been shown to reduce myocardial in• flammation associated with the chronic noninfectious phase of murine Coxsackie virus B3 myocarditis (5) . These in• terventions-for example, thymectomy-characteristically have universally impaired all T cell populations. Thus, a specific point of alteration of immunoregulation cannot be discriminated in these studies. Focused interventions against mononuclear sUbpopulations are not available, but altera• tions of these subpopulations may well have relevance to our results.
Possible immunomodulating effects of ibuprofen. The mechanism of immunomodulation by nonsteroidal anti-in• flammatory drugs during Coxsackie virus B3 infection of myocardium is of great interest. A growing body of theoretic knowledge suggest that increased inflammation and ne• crosis might occur in animals infected with Coxsackie virus B3 and treated with nonsteroid anti-inflammatory drugs. In the acute phase of myocarditis, the highly necrotic myo• cardial lesions do not appear to be secondary to impaired viral clearance, a phenomenon shown to be dependent on relatively intact monocyte and humoral antibody function (9). Although we do not have serologic evidence of B cell Coxsackie virus B3 responses, the lack of detectable virus at both 7 and 14 days after infection implies that clearance mechanisms were operative.
Ibuprofen, a phenylpropionate, blocks cyclooxygenase and lipooxygenase activity and subsequent formation of the inflammatory mediators prostaglandin E 2 , prostaglandin F2 and thromboxane A 2 . Nonsteroid anti-inflammatory drugs also have inhibitory effects on neutrophils that are not de• pendent on prostaglandin inhibition (4). These blocking mechanisms, recently shown to have cardioprotective ef• fects during myocardial ischemia (10), should theoretically reduce viral-mediated inflammation and would not explain the marked disparity between the experimental groups in this study. Although the immunomodulating effects of ibu• profen on prostaglandin-sensitive mononuclear subpopula• tions have not been extensively studied, available evidence suggests that cyclooxygenase blockers may inhibit the ac• tions of a population of prostaglandin-secreting, mononu• clear suppressor cell populations (11,12). The prostaglandin E series can also inhibit the production or action of inter• leukin-2 (13). Thus, the inhibition of prostaglandin E me• diators by nonsteroid anti-inflammatory drugs could enhance amplification of a cytotoxic population as they also inhibit the emergence of an immunoregulatory suppressor cell pop• ulation. The end result would strongly favor a marked in• crease in both specific and autoimmune myocardial cell JACC Vol. 6. No.5
November 1985: 1078-82 necrosis during Coxsackie virus B3 infection (14) . Con• versely, the mechanism of increased necrosis may be on a more mechanistic basis. Inhibition of prostaglandin synthe• sis may have negative effects on coronary flow or coronary vascular reactivity that enhance viral-induced cytotoxicity.
Conclusions. The superimposition of a perturber of prostaglandin synthesis (ibuprofen) during the acute and early chronic phase of Coxsackie virus B3 murine myocar• ditis leads to a marked exacerbation of both inflammatory and necrotic foci in the drug-treated animals. The Coxsackie virus B3 model appears useful for further study of both favorable and detrimental effects of immunomodulating drugs. The analysis of the morphologic outcomes after use of these immunomodulators may also lead to further understanding of inflammatory cell kinetics during viral infection of the heart and may identify important considerations in the use or nonuse of these drugs in appropriate clinical situations.
